F351 Phase 3 Development in China for NASH-Related Liver Fibrosis
A development program for F351 targeting liver fibrosis caused by NASH (MASH), with a Phase 3 clinical trial to be initiated in China and global expansion also under consideration.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.